… % of the patients in this study received erlotinib as a fourth-line or subsequent treatment,
the results from this study were similar to those of clinical studies. We deduce that erlotinib is …

… routine in patients with adenocarcinoma, and as a consequence seven EGFR … patients in
our study (1.5%) received erlotinib as first-line treatment. All patients were treated with erlotinib …

… patients receiving erlotinib treatment, the outcomes of the elderly (≥75 years) and younger
(<75 years) groups of patients were similar in our population‑based observational study. …

… erlotinib use in squamous NSCLC. This article reports the results of an observational study
(PEPiTA: Patient … of use of second-line erlotinib in patients with stage IIIB/IV squamous …

… used as 1L monotherapy was erlotinib (66%). Small numbers of patients received an EGFR-…
have been a factor in this study as the majority of patients did not receive subsequent 2L …

… A serious limit of our observational study is that it was not … of the Erlotinib registration in
Italy 9 ) to March 2010 (date of the Gefitinib registration in Italy 9 ), patients treated with erlotinib …

… Patients were randomised to maintenance erlotinib 150 mg daily for 2 years or observation.
Primary endpoint was progression-free survival (PFS) by RECIST in combination with GCIG …

… Patients harboring de novo T790M or using more than one EGFR-TKI were … patients enrolled,
the overall T790M acquisition rate was 52.8%. The patients treated with gefitinib, erlotinib …

… study was to evaluate the efficacy of erlotinib, one of the epidermal growth factor receptor-tyrosine
kinase inhibitors (EGFR‑TKIs), in patients … in patients prescribed first‑line erlotinib for …

… Efficacy and tolerability of erlotinib for elderly patients was not numerically inferior to that
reported in younger patients. Erlotinib could be considered for elderly patients with recurrent/…